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Various 2-propen-1-ones react with malononitrile under basic catalysis to yield cy-
clohexanol derivatives. This happens via double Michael reaction of malononitrile with
propenone, followed by intramolecular cyclization under basic conditions (1–3). On the
other hand, reaction of 1,3-diaryl-2-propen-1-ones with malononitrile in the presence of
a sufficient amount of alkoxide anion led to the formation of 2-alkoxy-3-cyanopyridines
(1–4). Numerous condensed pyridine carbonitrile systems were obtained under similar
conditions by the reaction of malononitrile with various ,-unsaturated ketones (5–9).
In the present work, the reaction of 1-(2-thienyl or furanyl)-3-(2-hydroxyphenyl)-2-pro-
pen-1-ones with malononitrile in the presence of a sufficient amount of alkoxide anion
was investigated. The hydroxyl group might behave as an active nucleophilic centre, af-
fording condensed 5H-1benzopyrano3,4-cpyridine derivatives. The synthesis of this
condensed heterocyclic system is interesting because of the potential biological activities
associated with its structure, such as antipsychotic dopamine D4 receptor antagonist
(10), cancer chemopreventive (11), antibacterial (including anti-tubercular) (12), antirhe-
umatic (13), against Alzheimer disease, Parkinson’s disease, anxiety, depression, allergic
responses and sedation (14). On the other hand, polysubstituted pyridines, especially
the 3,5-pyridinedicarbonitriles, are interesting as antioxidants and NADH co-enzyme
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In continuation of our search for new substituted pyridi-
ne based anti-inflammatories, reaction of 1-(2-thienyl or
furanyl)-3-(2-hydroxyphenyl)-2-propen-1-ones (1) with
malononitrile in alcoholic KOH solution afforded a mix-
ture of 4-alkoxy-2-(2-thienyl or furanyl)-5H-1benzopy-
rano3,4-cpyridine-5-ones (2) and 2-alkoxy-4-amino-6-
(2-thienyl or furanyl)-3,5-pyridinedicarbonitriles (3). So-
me of the synthesized compounds were evaluated for
their anti-inflammatory and analgesic activities compa-
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analogues that mediate hydrogen transfer in biological systems (15), and for their anti-
histaminic (16), anti-inflammatory and analgesic activity (17–19).
EXPERIMENTAL
Melting points were determined on the Electrothermal 9100 melting point appara-
tus (Electrothermal, UK) and are uncorrected. Microanalytical data (Elementar, Vario EL,
USA) were found within  0.4% of the theoretical values. The IR spectra (KBr) were re-
corded on a FT-IR NEXCES spectrophotometer (Shimadzu, Japan). The 1H NMR spectra
were measured with a Jeol ECA 500 MHz (Japan) in DMSO-d6 or CDCl3 and chemical
shifts were recorded in d ppm relative to TMS. Mass spectra (EI) were run at 70 eV with
a Finnigan SSQ 7000 spectrometer (Thermo-Instrument System Incorporation, USA). The
reactions were followed by TLC (silica gel, aluminum sheets 60 F254, Merck, Germany).
The starting compounds 1-(2-thienyl or furanyl)-3-(2-hydroxyphenyl)-2-propen-
-1-ones (1a-c) were prepared according to previously reported procedures (20).
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Syntheses of 4-alkoxy-2-(2-thienyl or furanyl)-5H-1benzopyrano3,4-cpyridine-
-5-ones (2a-f) and 2-alkoxy-4-amino-6-(2-thienyl or furanyl)-3,5-
-pyridinedicarbonitriles (3a-f)
General procedure. – A mixture of propene-1-ones (1a-c) (10 mmol) and 0.6 g malono-
nitrile (10 mmol) in 25 mL of alcoholic potassium hydroxide (absolute methanol or 4%
ethanol) was stirred at room temperature for appropriate time. The separated solid was
collected by filtration, washed with water and purified by silica gel preparative chroma-
tography to afford compounds 2a-f and 3a-f, respectively (Scheme 1). For compounds
4-methoxy-2-(2-thienyl)-5H-1-benzopyrano3,4-cpyridin-5-one (2a), 4-ethoxy-2-(2-thi-
enyl)-5H-1benzopyrano3,4-cpyridin-5-one (2b), 4-methoxy-2-(2-thienyl)-5H1-3-me-
thoxybenzopyrano-3,4-cpyridin-5-one (2c) and 4-ethoxy-2-(2-thienyl)-5H-1-3-metho-
xybenzopyrano-3,4-cpyridin-5-one (2d) the reaction time was 72 h and eluent for chro-
matography was chloroform/light petroleum (60–80 °C) (3:1, V/V). For 4-methoxy-2-
-(2-furanyl)-5H-1benzopyrano3,4-cpyridine-5-one (2e) and 4-ethoxy-2-(2-furanyl)-5H-
-1benzopyrano3,4-cpyridine-5-one (2f) the reaction time was 96 h and eluent for chro-
matography was chloroform/light petroleum (60–80 °C) (5:1, V/V). The same eluent was
used for 4-amino-2-methoxy-6-(2-thienyl)-3,5-pyridinedincarbonitrile (3a), 4-amino-2-
-ethoxy-6-(2-thienyl)-3,5-pyridinedicarbonitrile (3b), amino-2-methoxy-6-(thienyl)-3,5-
-pyridinedicarbonitrile (3c) yield (30%), identified as 3a by m.p., mixed m.p., TLC and
spectral data in comparison with authentic sample, 4-amino-2-ethoxy-6-(2-thienyl)-
-3,5-pyridinedicarbonitrile (3d) yield (20%); identified as 3b by m.p., mixed m.p., TLC
and spectral data in comparison with authentic sample, 4-amino-2-methoxy-6-(2-fra-
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nyl)-3,5-pyridinedicarbonitrile (3e), and 4-amino-2-ethoxy-6-(2-furanyl)-3,5-pyridinedi-
carbonitrile (3f)
Pharmacology
Animals. – Animals were obtained from the animal house colony of the National Re-
search Center, Cairo, Egypt. All animals were allowed free access to water and were
kept on a constant standard diet.
All procedures involving animals were carried out in accordance with the guide for
the care and use of laboratory animals (National Academy of Science of Egypt) and were
approved by the Animals Studies Committee at Washington University.
Adult male albino rats, weighing 150–180 g, were fasted for 12 hours and used for
determining the anti-inflammatory activity. Adult Swiss Webster mice of both sexes,
weighing 20–25 g, were fasted for 12–24 hours and used for determining the analgesic
activity and LD50.
Evaluation of anti-inflammatory activity. – The inhibitory activity of the studied com-
pounds on carrageenean-induced rat’s paw edema was determined according to the
method of Winter et al. (21) (Table III).
Groups of adult male albino rats (150–180 g), 8 animals each, were orally dosed with
tested compounds at a dose of 2.5–5.0 mg kg–1 one hour before carrageenean challenge.
Foot paw edema was induced by subplantar injection of 0.05 mL of 1% suspension of
carrageenean in saline into the plantar tissue of one hind paw. An equal volume of sali-
ne was injected into the other hind paw and served as control. Four hours after drug ad-
ministration the animals were decapitated, blood was collected and the paws were rap-
idly excised.
The average weight of edema was estimated for the treated as well as for the control
group and the percentage inhibition of edema was evaluated. Diclofenac potassium (2.5
and 5 mg kg–1) was employed as standard reference against which the test compounds
were compared (25).
Estimation of plasma prostaglandin E2 (PGE2). – This is an ELISA (Enzyme-Linked Im-
munosorbent Assay) for the quantitative analysis of Prostaglandin E2 levels in biological
fluid (22). The test kit (Merck, Germany) operates on the basis of competition between
the enzyme conjugate and the PGE2 in the sample for a limited number of binding sites
on the antibody coated plate.
The sample heparinized blood samples collected from rats treated with anti-inflam-
matory drugs (n = 8), plasma was separated by centrifugation at 12000  g for 2 min at
40 °C and immediately stored frozen –20 °C until use or standard solution, is first ad-
ded to the microplate. Next, the diluted enzyme conjugate is added and the mixture is
shaken and incubated at room temperature for one hour. During the incubation, compe-
tition for binding sites is taking place. The plate is then washed removing all the unbound
material. The bound enzyme conjugate is detected by the additions of substrate, which
generates an optimal color after 30 minutes. Quantitative test results may be obtained by
measuring and comparing the absorbance reading for the samples against the standards
with a microplate reader at 650 nm. The extent of color development is inversely propor-
tional to the amount of PGE2 in the sample or standard; e.g., the absence of PGE2 in the
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sample will result in a bright blue color, whereas the presence of PGE2 will result in yel-
low color development.
Evaluation of analgesic activity
Sixty Swiss Webster mice were divided into 10 groups. One group was kept as con-
trol (received 0.1 mL saline s.c.), the second group received vehicle (0.1 mL 1% of gum
acacia), and the third received diclofenac potassium in a dose of 2.5 mg kg–1 (diclofenac
180
H. M. Hosni and M. M. Abdulla: Anti-inflammatory and analgesic activities of some newly synthesized pyridinedicarbonitrile and
benzopyrano-pyridine derivatives, Acta Pharm. 58 (2008) 175–186.





































































































All results are significant different from control values at p  0.005.
a 0.1 mL saline.
suspended in 2% gum acacia suspension) as a reference drug, while the other groups re-
ceived the test compounds suspended in 2% gum acacia, s.c. Mice were dropped gently
into a dry glass beaker of 1 L capacity maintained at 55–55.5 °C. Normal reaction time in
seconds for all animals was determined at time intervals of 10, 20, 30, 60, 90, and 120 mi-
nutes. This is the interval extending from the moment when the mouse reaches the hot
beaker till the animal licks its feet or jumps out of the beaker (dose 5 mg kg–1). The rela-
tive potencies to diclofenac potassium were determined (Table IV).
Determination of acute toxicity (LD50)
The LD50 was determined on mice by injecting increasing doses of test compounds
calculating the dose that kills 50% of the animals, according to Austen et al. (23) (Table V).
RESULTS AND DISCUSSION
Reaction of 1-(2-thienyl)-3-(2-hydroxyphenyl)-2-propen-1-one (1a), 1-(2-thienyl)-3-
-(2-hydroxy-3-methoxyphenyl)-2-propen-1-one (1b) or 1-(2-furanyl)-3-(2-hydroxyphe-
nyl)-2-propen-1-one (1c) with malononitrile in alcoholic (methanolic or ethanolic) potas-
sium hydroxide at room temperature with stirring afforded a mixture of two products,
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10 20 30 60 90 120
Control 0 0 0 0 0 0
2a 0.45  0.02 0.56  0.01 0.67  0.02 1.00  0.01 1.20  0.01 1.80  0.01
2b 0.40  0.01 0.50  0.01 0.60  0.01 0.99  0.01 1.00  0.01 1.76  0.01
2c 0.30  0.01 0.40  0.01 0.50  0.01 0.70  0.01 0.90  0.01 1.20  0.01
2d 0.30  0.01 0.40  0.01 0.49  0.01 0.66  0.01 0.79  0.01 1.00  0.01
2e 0.61  0.02 0.71  0.02 0.81  0.02 0.90  0.02 1.20  0.01 2.20  0.01
2f 0.86  0.01 1.21  0.01 1.47  0.01 1.30  0.01 2.24  0.01 2.33  0.02
3a 0.45  0.01 0.55  0.01 0.66  0.01 1.00  0.01 1.12  0.01 1.79  0.01
3b 1.25  0.01 2.00  0.01 2.28  0.01 2.80  0.01 3.00  0.01 3.12  0.01
3c 0.45  0.01 0.55  0.02 0.66  0.01 1.00  0.01 1.12  0.01 1.79  0.01
3d 1.25  0.01 2.00  0.01 2.28  0.01 2.80  0.01 3.00  0.01 3.12  0.01
3e 0.30  0.01 0.40  0.01 0.40  0.01 0.60  0.01 0.70  0.01 1.10  0.01
3f 0.61  0.02 0.81  0.01 1.25  0.01 1.43  0.01 1.60  0.01 1.81  0.01
Diclofenac
potassium
1.05  0.01 1.06  0.01 1.04  0.01 1.01  0.01 1.02  0.01 1.03  0.01
All results are significantly different from control at p  0.005.
which were isolated by silica gel preparative chromatography. Their structures were es-
tablished as 4-alkoxy-2-(2-thienyl or furany1)-5H1benzopyrano3,4-cpyridin-5-ones
(2a-f) and 2-alkoxy-4-amino-6-(2-thienyl or furanyl)-3,5-pyridinedicarbonitries (3a-f) ba-
sed on spectroscopic and elemental analysis data (Tables I and II).
The IR spectra of 2a-f did not show any absorption assignable to nitrile vibration.
However, a strong band due to carbonyl stretching vibration was observed at n 1738–
1730 cm–1. 1H NMR spectra of 2a-f showed the presence of an alkoxide residue, confirm-
ing the involvement of either methoxide (singlet at d 4.0–4.21 ppm) or ethoxide (triplet
at d 1.7–1.50, quartet at d 4.73–4.62 ppm).
The formation of 2 was assumed to take place via Michael addition of active methy-
lene malononitrile to the -carbon of 2-propen-1-ones (1a-c). Then cyclization due to the
addition of the alkoxide residue at one of the nitrile groups with subsequent nucleophi-
lic attack of the hydroxyl oxygen at the other nitrile function took place. Hydrolysis of
the imino group under these reaction conditions afforded eventually the 4-alkoxy-2-
-(thienyl or furanyl)-5H-1benzopyrano3,4-cpyridine-5-ones (2a-f) (Scheme 1).
The IR spectra of 3a-f did not show any absorption corresponding to carbonyl func-
tion, which was present in the starting material. On the other hand, bands assignable to
the amino stretching vibration appeared at n 3343, 3241 cm–1 beside the nitrile stretching
vibration bands at n 2217–2214 cm–1. 1H NMR spectra of 3a-f exhibited the alkoxide resi-
due (singlet at d 3.28–3.00 ppm) for the methoxide and (triplet at d 1.70–1.50, quartet at d
4.73–4.62 ppm) for the ethoxide protons, in addition to the amino singlet signal at d
7.90–7.60 ppm.
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Table V. Acute toxicity (LD50) of the synthesized compounds
Compd. No. LD50 (mg kg–1)a
2a 2228.31  0.13
2b 1192.10  0.12
2c 1273.61  0.11
2d 1012.61  0.11
2e 2345.00  0.14
2f 2368.00  0.15
3a 1211.19  0.11
3b 1966.00  0.16
3c 1211.19  0.12
3d 1966.00  0.15
3e 1252.61  0.11
3f 1524.00  0.16
Diclofenac potassium 1988.00  0.29
a Mean  SD, n = 24.
All results are significantly different from control at p  0.005.
Formation of 3a-f presumably took place through cleavage of the starting propeno-
nes 1a-c, giving rise to the (un)substituted benzoate ester, which in turn interacted with
the active methylene malononitrile dimer (formed under the basic reaction conditions).
Subsequently, cyclization took place due to alkoxide nucleophilic attack at one of the nit-
rile groups, finally giving the 4-amino-2-alkoxy-6-(2-thieny or furanyl)-3,5-pyridinedi-
carbonitriles 3a-f.
All the tested compounds showed potent anti-inflammatory activity and PEG2 inhi-
bition at two dose levels (2.5 and 5 mg kg–1). Compounds 3a, 3c (3b, 3d) showed high
protection against induced edema, more than 90%, with high percentage inhibition of
PEG2, higher than 74%, whereas compounds 2f, 2a, 2b, 2c, 2d showed moderate potency.
The degree of potency in descending order is: 3a, 3c (3b, 3d), 2f, 2a, 2b, 2c, 2d, 3e, 3f, 2f
and 2e.
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1,4-Michael addition
















































All tested compounds exhibited analgesic activities (Table IV) that lasted for 120 mi-
nutes and the potency increased with time. The most potent compounds were (3d, 3d),
nearly 3 times more potent than diclofenac, while compound 2f was 2 times more potent
than diclofenac. The degree of potency in descending order is (3a, 3b), 2f, 2e, 3f, 2a (3c,
3a), 2b, 2c, 3e and 2d. On the basis of mass-calculated dosage all the tested compounds
were more potent than diclofenac potassium (Table III).
The newly synthesized compounds have a high safety margin due to their high
LD50 (Table V). Compounds 2f, 2e, 3a are safer than diclofenac whereas compounds (3d,
3b), 3f, 2c, 3e, 3a, 3c and 2d are less safe than diclofenac and they are arranged in des-
cending order of safety.
Five membered ring system with one heteroatom is essential for both anti-inflam-
matory and analgesic activity, whereas polycyclic ring systems play an important role in
increasing these activities. Thiophene sharply increases both anti-inflammatory and
analgesic activity.
CONCLUSION
Newly synthesized thienylpyridine carbonitriles and furanyl benzopyranopyridi-
nes have proven that both pyridine nucleus and five-membered ring with one hetero-
atom seem to be essential for anti-inflammatory and analgetic activities. A number of
substituents is aimed at studying for their contribution to pharmacological activity.
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S A @ E T A K
Protuupalno i analgetsko djelovanje novih derivata
piridindikarbonitrila i benzopiranopiridina
HANAA M. HOSNI i MOHAMED M. ABDULLA
U nastavku istra`ivanja derivata piridina s potencijalnim protuupalnim djelova-
njem sintetizirani su 4-alkoksi-2-(2-tienil ili furanil)-5H-1benzopirano3,4-cpiridin-5-
oni (2) i 2-alkoksi-4-amino-6-(2-tienil ili furanil)-3,5-piridindikarbonitrili (3). Smjesa spo-
jeva 2 i 3 dobivena je reakcijom 1-(2-tienil ili furanil)-3-(2-hidroksifenil)-2-propen-1-ona
(1) s malononitrilom u alkoholnoj otopini KOH. Neki od sintetiziranih spojeva testirani
su na protuupalno i analgetsko djelovanje, uz diklofenak kalij kao pozitivnu kontrolu. U
radu su dani detaljni sintetski, spektroskopski i toksikolo{ki podaci.
Klju~ne rije~i: piridindikarbonitril, benzopiranopiridin, spojevi s protuupalnim i analgetskim djelo-
vanjem
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